Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The world of chronic lymphocytic leukemia (CLL) research is awash with prognostic markers. However, very few of the current group play a clearly defined role in the pathology of this disease and even fewer represent a tractable therapeutic target. One such marker that fulfils both of these criteria is the integrin CD49d. This molecule been implicated in the capacity of CLL cells to migrate into lymphoid tissues and there is a CD49d blocking antibody, Natalizumab, currently in clinical trials. Here we carried out the largest multi-centre evaluation of CD49d as a prognostic marker in 652 primary CLL samples. We confirm that CD49d is predictive for time to first treatment (P<0.0001) and overall survival (P<0.0001) and increases the prognostic power of CD38, ZAP-70 and IGHV gene mutation status in concordant cases. Furthermore, CD49d retained independent prognostic significance in multivariate analysis. In contrast to previous studies, we showed no correlation between CD49d expression and in vitro resistance to fludarabine in liquid cultures (P=0.28) but CD49d(hi) cells were significantly more resistant than CD49d(lo) cells when assays were carried out on fibronectin-coated plates (P=0.03). Furthermore, we showed for the first time that the expression of CD49d is strongly associated with expression of the chemokine receptor CXCR4 suggesting a co-ordinated role for these molecules in the trafficking of CLL cells to the lymphoid tissues. Taken together, our data support the introduction of CD49d into routine immunophenotyping panels for CLL and indicate that the therapeutic targeting of this molecule may prove useful in this disease.

Original publication

DOI

10.1016/j.leukres.2010.10.022

Type

Journal article

Journal

Leuk Res

Publication Date

06/2011

Volume

35

Pages

750 - 756

Keywords

ADP-ribosyl Cyclase 1, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Biomarkers, Tumor, Cell Survival, Flow Cytometry, Humans, Immunoglobulin Heavy Chains, Immunoglobulin Variable Region, Integrin alpha4, Leukemia, Lymphocytic, Chronic, B-Cell, Middle Aged, Multivariate Analysis, Mutation, Prognosis, Receptors, CXCR4, Survival Analysis, Tumor Cells, Cultured, Vidarabine, ZAP-70 Protein-Tyrosine Kinase